UMDNJ

Cepheid's Xpert MTB/RIF test received a vote of confidence for its ability to diagnose TB and rifampicin resistance in remote and resource-poor regions of the world, according to the results of a New England Journal of Medicine study.

Princeton University, Point-2-Point Genomics, PHRI at UMDNJ/NJMS, and NuGen Technologies awarded US patents.

Under the deal, Biosearch has the exclusive rights to manufacture, catalogue, and sell validated RNA FISH probes, assays, and kits in the research, applied markets, and in vitro diagnostic fields.

The UK-based company will offer the toolkit through a single license that combines IP it licensed from Brandeis University and PHRI Properties, the tech-transfer arm of the University of Medicine and Dentistry of New Jersey.

Cepheid and the University of Medicine and Dentistry of New Jersey will work on developing a 10-color detection technology for the firm's GeneXpert System.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.